Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Grail’s Galleri blood test just failed a make-or-break NHS trial, missing its primary endpoint and reviving the uncomfortable question: Does earlier detection actually change outcomes, or just the timeline for diagnoses?
And there’s more news out of the FDA: The agency has installed an AI industry vet to steer digital health, and new CDER chief Tracy Beth Høeg tells staff she’s keen to revisit SSRIs in pregnancy and scrutinize RSV monoclonals.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
